■ Related Company: OLYMVAX (SH688319, share price: RMB 17.28, market capitalization: RMB 7 billion)
■ Core Competitiveness: Core products such as Tetanus Vaccine, Adsorbed, AC-Hib Combined Vaccine, and Recombinant Staphylococcus Aureus Vaccine have huge market potential; there are mature R&D industrialization platforms and rich product pipelines, etc.
■ Comments by the Institutions: OLYMVAX is a leading enterprise of adult tetanus vaccines, and has obtained good achievements in Phase II clinical study of Staphylococcus Aureus Vaccine; the Company’s three major products are expected to drive a steady growth; the Company has continually increased its R&D investment to enrich the pipeline varieties and make full preparations for long-term growth.
■ Concept: Bio-medicine, Bio-vaccine
Vaccines have played an irreplaceable role from vaccinia vaccination against smallpox in the 18th century in England to the national prevention and control of pandemic diseases typified by COVID-19 in the 21st century.
As an important means to fight against infectious diseases, the emergence of vaccines can be regarded as one of the most important milestones in the history of human public health.
Throughout the vaccine development history of more than 200 years, the emergence of every new vaccine is almost accompanied by the iteration of technological pathways and the innovation in prevention and treatment of specific diseases. Moreover, vaccine is considered a high-barrier industry due to its high investment and long development cycle.
Even so, vaccine, known as the “light at the tunnel end” has attracted generations of scientists and pharmaceutical companies.
In 2021, OLYMVAX was successfully listed on the Science and Technology Innovation Board, striving to achieve high-quality development on this competitive and dynamic capital platform. Currently, the Company has entered the Phase III clinic trials of Staphylococcus Aureus Vaccine. If the vaccine is successfully launched, it is expected to fill the gap in the world and resolve the problem of super drug-resistant bacteria.
On the third anniversary of the opening of the Science and Technology Innovation Board, Ms. Fan Fan, one of the actual controllers of OLYMVAX, gave an exclusive interview to a reporter from the National Business Daily, explaining the development plan of “bacterial vaccine + virus vaccine” of OLYMVAX in detail.